NEUROLOGY 2004;62:1432-1434
© 2004 American Academy of Neurology
Brief Communications
Measurement error of two different techniques for brain atrophy assessment in multiple sclerosis
M. P. Sormani, PhD,
M. Rovaris, MD,
P. Valsasina, MD,
J. S. Wolinsky, MD,
G. Comi, MD and
M. Filippi, MD
From the Neuroimaging Research Unit (Drs. Sormani, Rovaris, Valsasina, and Filippi) and Clinical Trials Unit (Dr. Comi), Department of Neurology, Scientific Institute and University Ospedale San Raffaele, Milan, and Unit of Clinical Epidemiology and Trials (Dr. Sormani), National Institute for Cancer Research, Genoa, Italy; and University of Texas Health Science Center at Houston (Dr. Wolinsky).
Address correspondence and reprint requests to Dr. M. Filippi, Neuroimaging Research Unit, Department of Neurology, Scientific Institute and University Ospedale San Raffaele, via Olgettina 60, 20132 Milan, Italy; e-mail: filippi.massimo{at}hsr.it
The measurement errors associated with two techniques for brain atrophy assessment in multiple sclerosis (MS) were estimated. The measurement error of a semiautomated, nonnormalized technique with partial brain coverage was about twofold higher than that of a fully automated, normalized technique with full brain coverage (Structural Image Evaluation of Normalized Atrophy software [SIENA]). As shown by the analysis of data from a clinical trial of glatiramer acetate, the use of SIENA increases the study power to detect a treatment effect on brain volume changes in MS patients.
Received September 26, 2003.
Accepted in final form December 10, 2003.
Drs. Sormani, Rovaris, Wolinsky, Comi, and Filippi have received honoraria from Teva Pharmaceutical Industries. (All of the above except for Dr. Rovaris received in excess of $10,000.)
This article has been cited by other articles:
|
|
|
|
 
B Healy, P Valsasina, M Filippi, and R Bakshi
Sample size requirements for treatment effects using gray matter, white matter and whole brain volume in relapsing-remitting multiple sclerosis
J. Neurol. Neurosurg. Psychiatry,
November 1, 2009;
80(11):
1218 - 1224.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. R. Altmann, B. Jasperse, F. Barkhof, K. Beckmann, M. Filippi, L. D. Kappos, P. Molyneux, C. H. Polman, C. Pozzilli, A. J. Thompson, et al.
Sample sizes for brain atrophy outcomes in trials for secondary progressive multiple sclerosis
Neurology,
February 17, 2009;
72(7):
595 - 601.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. D. Sluimer, W. M. van der Flier, G. B. Karas, N. C. Fox, P. Scheltens, F. Barkhof, and H. Vrenken
Whole-Brain Atrophy Rate and Cognitive Decline: Longitudinal MR Study of Memory Clinic Patients
Radiology,
August 1, 2008;
248(2):
590 - 598.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Zivadinov, A. T. Reder, M. Filippi, A. Minagar, O. Stuve, H. Lassmann, M. K. Racke, M. G. Dwyer, E. M. Frohman, and O. Khan
Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis
Neurology,
July 8, 2008;
71(2):
136 - 144.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. P. Lisak
Neurodegeneration in multiple sclerosis: Defining the problem
Neurology,
May 29, 2007;
68(22_suppl_3):
S5 - S12.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. L. Arnold
Evidence for neuroprotection and remyelination using imaging techniques
Neurology,
May 29, 2007;
68(22_suppl_3):
S83 - S90.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Rovaris, G. Comi, M. Rocca, P. Valsasina, D. Ladkani, E. Pieri, S. Weiss, G. Shifroni, J. Wolinsky, M. Filippi, et al.
Long-term follow-up of patients treated with glatiramer acetate: a multicentre, multinational extension of the European/Canadian double-blind, placebo-controlled, MRI-monitored trial
Multiple Sclerosis,
May 1, 2007;
13(4):
502 - 508.
[Abstract]
[PDF]
|
|
|
|
|
|
|
N. Peters, M. Holtmannspotter, C. Opherk, A. Gschwendtner, J. Herzog, P. Samann, and M. Dichgans
Brain volume changes in CADASIL: A serial MRI study in pure subcortical ischemic vascular disease
Neurology,
May 23, 2006;
66(10):
1517 - 1522.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Krapf, S. P. Morrissey, O. Zenker, T. Zwingers, R. Gonsette, H. -P. Hartung, and the MIMS Study Group
Effect of mitoxantrone on MRI in progressive MS: Results of the MIMS trial
Neurology,
September 13, 2005;
65(5):
690 - 695.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. A. Bermel, S. R. Puli, R. A. Rudick, B. Weinstock-Guttman, E. Fisher, F. E. Munschauer III, and R. Bakshi
Prediction of Longitudinal Brain Atrophy in Multiple Sclerosis by Gray Matter Magnetic Resonance Imaging T2 Hypointensity
Arch Neurol,
September 1, 2005;
62(9):
1371 - 1376.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Enzinger, F. Fazekas, P. M. Matthews, S. Ropele, H. Schmidt, S. Smith, and R. Schmidt
Risk factors for progression of brain atrophy in aging: Six-year follow-up of normal subjects
Neurology,
May 24, 2005;
64(10):
1704 - 1711.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Oreja-Guevara, M. Rovaris, G. Iannucci, P. Valsasina, D. Caputo, R. Cavarretta, M. P. Sormani, P. Ferrante, G. Comi, and M. Filippi
Progressive Gray Matter Damage in Patients With Relapsing-Remitting Multiple Sclerosis: A Longitudinal Diffusion Tensor Magnetic Resonance Imaging Study
Arch Neurol,
April 1, 2005;
62(4):
578 - 584.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Hardmeier, S. Wagenpfeil, P. Freitag, E. Fisher, R. A. Rudick, M. Kooijmans, M. Clanet, E. W. Radue, L. Kappos, and for the European IFNss-1a in Relapsing MS Dose Com
Rate of brain atrophy in relapsing MS decreases during treatment with IFN{beta}-1a
Neurology,
January 25, 2005;
64(2):
236 - 240.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
